Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease.

@article{Mammen2012MacrolideTF,
  title={Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease.},
  author={Manoj J. Mammen and Sanjay Sethi},
  journal={Polskie Archiwum Medycyny Wewnetrznej},
  year={2012},
  volume={122 1-2},
  pages={
          54-9
        }
}
Acute exacerbations are a major contributor to health care costs and a leading cause of death in patients with chronic obstructive pulmonary disease (COPD). A reduction in acute exacerbations of COPD (AECOPD) would lead to significant improvements in patient well-being and survival. Bacterial and viral infections cause a majority of AECOPD episodes; however, with the exception of influenza and pneumococcal vaccines, preventative therapies for exacerbations do not directly address these… Expand
Macrolide Therapy Decreases Chronic Obstructive Pulmonary Disease Exacerbation: A Meta-Analysis
TLDR
Macrolide therapy was effective and safe in decreasing the frequency of exacerbations in patients with COPD and might provide a significant benefit but only when therapy lasts more than 6 months. Expand
Relationship between Azithromycin Susceptibility and Administration Efficacy for Nontypeable Haemophilus influenzae Respiratory Infection
TLDR
The results of this work link the bactericidal and anti-inflammatory effects of AZM and frame the efficacy of this antibiotic against NTHI respiratory infection. Expand
Translational studies of viral-induced asthma and COPD exacerbations
TLDR
Both in vitro and in vivo models are explored, revealing important and potential drug target molecules such as TSLP, IL-33 and IL-25 involved in triggering or maintaining of viral-triggered respiratory exacerbations. Expand
Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know
  • I. Barjaktarevic, Michael Campos
  • Medicine
  • Therapeutic advances in chronic disease
  • 2021
TLDR
The rationale and available evidence for non-pharmacological and pharmacological interventions in AATD, which consist of administering exogenous alpha-1 antitrypsin protein intravenously, are discussed. Expand
Chronic obstructive pulmonary disease (COPD): Evaluation from clinical, immunological and bacterial pathogenesis perspectives
TLDR
A non-conventional, biocidal treatment is offered that may be effective for COPD airway infections as well as with combinations of current antibiotic regimens for more effective treatment outcomes and relief for patients with COPD. Expand
Emerging concepts and therapies for chronic obstructive pulmonary disease.
TLDR
The growing awareness that COPD is a heterogeneous disease composed not only of differing phenotypes but also having significant extrapulmonary comorbidities have opened new avenues of research and interdisciplinary collaboration that will further enable us to offer personalized care to patients. Expand
Combination of erythromycin and dexamethasone improves corticosteroid
TLDR
The results demonstrate that the combination therapy of EM and Dex can restore corticosteroid sensitivity through inhibition of the PI3K-δ/Akt pathway and enhancing GRα expression. Expand
Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data.
TLDR
Clinical cure rates in CARTI subjects treated with azithromycin were higher for Azi-S SPN compared withAzi-R SPN, and the cure rates were not different for subjects infected with LLAR-SPN versus HLAR- SPN. Expand
Mesenchymal stem/stromal cells engineered to express the protease inhibitor alpha-1 antitrypsin for the treatment of inflammatory lung diseases
TLDR
The present study provides the first in vivo proof of concept for the treatment of emphysematous COPD using engineered AAT-MSCs, a novel cell product composed of mesenchymal stem/stromal cells genetically modified to express the protease inhibitor alpha-1 antitrypsin (AAT). Expand
A Review on Chronic Obstructive Pulmonary Disease
In the ancient age COPD has a variable natural history and not all individuals follow the same course about 15-20% of smokers develop clinically significant COPD. It is characterized by the airflowExpand
...
1
2
...

References

SHOWING 1-10 OF 33 REFERENCES
Azithromycin for prevention of exacerbations of COPD.
  • D. Hahn
  • Medicine
  • The New England journal of medicine
  • 2011
TLDR
The use of daily azithromycin reduced the frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD) and the possible role of the immunomodulatory effects of macrolides in the discussion of their results is not mentioned. Expand
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.
TLDR
Macrolide therapy was associated with a significant reduction in exacerbations compared with placebo and may be useful in decreasing the excessive disease burden in this important patient population. Expand
[Pharmacoeconomic study of antibiotic therapy for exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in Latin America].
TLDR
The direct health care costs of treating patients with exacerbations of chronic bronchitis and COPD in Argentina, Brazil, Colombia, Ecuador, Mexico, Peru, and Venezuela are analyzed, applying the real cost of drugs and medical acts in those 7 countries to the pattern of treatment and outcomes obtained from a study carried out in primary care settings in Spain. Expand
Infection as a comorbidity of COPD
  • S. Sethi
  • Medicine
  • European Respiratory Journal
  • 2010
TLDR
Enhanced understanding of the host–pathogen interaction is needed to better prevent and treat respiratory tract infection in COPD. Expand
The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD.
TLDR
Treatment of COPD with clarithromycin during the clinical stable state yields no clinical advantages and therefore cannot be recommended as means of eliminating sputum bacteria or preventing infective exacerbations. Expand
Susceptibility to exacerbation in chronic obstructive pulmonary disease.
TLDR
Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype, which has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity. Expand
Macrolide antibiotics and cystic fibrosis
TLDR
The introduction of erythromycin as a treatment for diffuse panbronchiolitis has had a dramatic impact on mortality, increasing 10 year survival from 12.4–21.9% to over 90% in those colonised with P aeruginosa .3,4 Similar success has been reported with clarithromycin, roxithromyquin, and azithsromycin. Expand
Prophylactic antibiotic therapy for chronic bronchitis.
TLDR
Prophylactic antibiotics in chronic bronchitis / COPD have a small but statistically significant effect in reducing the days of illness due to exacerbations of chronic Bronchitis. Expand
Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD.
TLDR
Relapse from AECB was not related to the severity of underlying disease or to the severe severity of the acute exacerbation, and patients treated with antibiotics had significantly lower relapse rates than those who did not receive antibiotics. Expand
Preventing and managing exacerbations in COPD – critical appraisal of the role of tiotropium
  • D. Tashkin
  • Medicine
  • International journal of chronic obstructive pulmonary disease
  • 2010
TLDR
The mechanism whereby tiotropium reduces exacerbations is not due to an anti-inflammatory effect but more likely relates to its property of causing a sustained increase in airway patency and reduction inhyperinflation, thereby counteracting the tendency for respiratory insults to worsen airflow obstruction and hyperinflation. Expand
...
1
2
3
4
...